Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8714897 | Journal of the American Academy of Dermatology | 2018 | 35 Pages |
Abstract
Treatment with either certolizumab 400 mg or 200 mg every 2 weeks was associated with significant and clinically meaningful improvements in moderate-to-severe psoriasis. The 400-mg dose could provide additional clinical benefit. The safety profile was consistent with the therapeutic class.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Alice B. MD, PhD, Andrew MD, MBA, Diamant MD, Craig L. MD, Yves MD, Janice MPH, Luke MS, Catherine MD, PharmD, Daniel MD, Kristian MD,